~~<i id='1BDCD94DC6'><strike id='1BDCD94DC6'><tt id='1BDCD94DC6'><pre id='1BDCD94DC6'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：Wikipedia 2025-09-28 06:21:59 Page View：4

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Neutralizing antibodies against HIV shows promise in children
Next article： Novavax promises a turnaround & Lilly roils the obesity market

comprehensive

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

5:30VivekRamaswamyspeaksduringtheTurningPointActionConferenceatthePalmBeachCountyConventionCenter,Ju

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

FDA seeking to stop procedures at two unregulated stem cell clinics

StemcellsSpencerPlatt/GettyImagesFederalofficialsmovedonWednesdaytostoptwoclinicsfromcontinuingtooff